Healthcare / BiotechnologyCanadian Sec
$0.42
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-342239.00 · quality 35.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-32.0%
↓Gross Margin
44.4%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+38.4%
FCF CAGR
—
FCF margin
-804.2%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42556.0 · net income $-447788.0 · FCF $-342239.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $42556.00 | $42556.00 | $98522.00 | $43088.00 | $16048.00 |
| Net Income | $-447788.00 | $-447788.00 | $-339848.00 | $-1.8M | $-1.9M |
| EBITDA | $-471606.00 | $-471606.00 | $-357263.00 | $-1.7M | $-1.7M |
| EPS | -0.10 | -0.10 | -0.08 | -0.40 | -0.50 |
| Gross Margin | 44.4% | 44.4% | 73.2% | 95.8% | -924.6% |
| Operating Margin | -1108.2% | -1108.2% | -383.3% | -1931.3% | -11320.1% |
| Net Margin | -1052.2% | -1052.2% | -344.9% | -4134.7% | -12084.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.04 | 0.25 |
| Cash Flow | |||||
| Free Cash Flow | $-342239.00 | $-342239.00 | $-235118.00 | $-481054.00 | $-1.7M |
| Returns | |||||
| ROE | -32.0% | -32.0% | -33.3% | -137.1% | -64.7% |
| Valuation | |||||
| P/B | 1.39 | 1.39 | 0.63 | 0.79 | 0.85 |
| Growth & Yield | |||||
| Revenue Growth | -56.8% | -56.8% | 128.7% | 168.5% | — |
| EPS Growth | -25.0% | -25.0% | 80.0% | 20.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.10
Residual
+5.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.